Home
    • Plans Blog Contact
    INTERPACE BIOSCIENCES, INC. logo

    INTERPACE BIOSCIENCES, INC.

    IDXG
    Last price US$1.46
    Market cap US$39.3m
    12M price change 53.68%
    Loading the 12-month Mave Thesis and 1-month news signal

    Industry and sector peers, plus broader research alternatives

    View comparison
    IQVIA Holdings IncIQV Industry peer Agilent Technologies IncA Industry peer Thermo Fisher Scientific IncTMO Industry peer Zoetis IncZTS Sector peer
    Overview Earnings Report Price History News Competitors Earnings per Share Return on Equity Net Margin Share Buyback Leverage Financial Statements Financial Ratio
    Dashboard Funda..tals Prediction Screener Map

    INTERPACE BIOSCIENCES, INC. Overview

    Industry: Diagnostics & Research

    Sector: Healthcare

    Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test for the diagnosis and prognosis of pancreatic cancer; PanDNA, a molecular only version of PancraGEN that provides physicians a snapshot of a limited number of factors; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer. It primarily serves physicians, hospitals, and clinics. The company was formerly known as Interpace Diagnostics Group, Inc. and changed its name to Interpace Biosciences, Inc. in November 2019. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey. Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test for the diagnosis and prognosis of pancreatic canc Read More

    Mavefund brings filings, fundamentals, valuation, price history and news for INTERPACE BIOSCIENCES, INC. into one research view. The sections below show what strengthens or weakens the research case.

    Score

    Reported Results

    What the company reported, with filing details kept small.

    Filed May 14, 2026

    Quarterly result summary

    Revenue was $9M (reported). Operating income was $1.1M. Net income was $0.7M (-56% YoY).

    Revenue $9M reported
    Operating income $1.1M reported
    Net income $0.7M -56% YoY
    Adjusted EBITDA $1.6M reported

    What changed

    • Revenue reported to $9M.
    • Net income -56% YoY to $0.7M.

    Guidance / outlook

    we expect will support continued margin expansion as the year progresses.

    Earnings release Open filing

    Source: SEC EDGAR company-filed earnings materials. Dates are shown only for verification; review the source filing before relying on extracted report details.

    Other recent earnings materials
    SEC filing 8-K May 14, 2026 SEC filing 10-Q May 12, 2026 SEC filing 10-K/A Apr 30, 2026 SEC filing 8-K Apr 01, 2026 Earnings release Earnings release Apr 01, 2026 SEC filing 10-K Mar 30, 2026 SEC filing 8-K Jan 20, 2026 SEC filing 8-K Nov 12, 2025 Earnings release Earnings release Nov 12, 2025 SEC filing 10-Q Nov 12, 2025

    Prediction-grade evidence

    Recent News

    Company-relevant articles from sources that pass the Mave Signal relevance and reliability checks.

    No qualified company news in the last 14 days

    No recent article passed both the company-relevance and source-reliability checks. Research continues to use the other available filings, fundamentals, market data, and valuation inputs.

    Earnings Per Share

    Score 2.00/5
    INTERPACE BIOSCIENCES, INC. earns a low score, as its Earnings Per Share (EPS) has not shown continuous growth over the last six years. Notable counterparts in the sector with high scores includes Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    In Diagnostics & Research industry , IQVIA Holdings Inc , Agilent Technologies Inc , Thermo Fisher Scientific Inc are companies with high ratings.

    Return on Equity

    Score 2.53/5
    INTERPACE BIOSCIENCES, INC. stands out with a superior score in the Return on Equity (ROE) section, surpassing the sector median value and showcasing its strong performance in this metric. The top companies in the same sector include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    INTERPACE BI... IDXG US$39.3m
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Net Margin

    Score 1.53/5
    INTERPACE BIOSCIENCES, INC. olds a low score as its net margin consistently trails below the sector median value and doesn't exhibit continuous growth over the last six years; notable companies in the sector with commendable scores include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    INTERPACE BI... IDXG US$39.3m
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Share Buyback

    In Diagnostics & Research industry , IQVIA Holdings Inc , Agilent Technologies Inc , Thermo Fisher Scientific Inc are companies with high ratings.

    Leverage

    Score 1.59/5
    INTERPACE BIOSCIENCES, INC. registers a lower score in the category as a result of its elevated leverage ratio over the past six years compared to the sector median value. Conversely, other companies in the same sector, including Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc have achieved high scores.
    INTERPACE BI... IDXG US$39.3m
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Financial Statements

    Company-reported SEC EDGAR facts organized into the three core statements.

    Verified SEC statements load when this section enters view.

    Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.

    Financial Ratio

    Yearly Quarterly

    Financial
    Profitability
    Growth
    Cash Flow
    Financial Health
    Efficiency Ratios

    INTERPACE BIOSCIENCES, INC. logo

    INTERPACE BIOSCIENCES, INC.

    US$1.46

    US$3.13

    +114.7% vs price

    US$39.3m

    2.82%

    53.68%